ArticleBritish journal of cancer1996
High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci.
Article in British journal of cancer, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 49 citations in OpenAlex.
- Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer.Current oncology (Toronto, Ont.) · 2023Review
- Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer.BMC cancer · 2020Article
- The ABO Blood Group is an Independent Prognostic Factor in Patients with Ovarian Cancer.Journal of Cancer · 2019Article
- AB0 Blood Group and Ovarian Cancer Survival.Journal of Cancer · 2019Article
- Tuberous sclerosis complex 2 loss of heterozygosity in patients with lung disease and cancer.American journal of respiratory and critical care medicine · 2015Article
- Effect of blood type on survival of Chinese patients with esophageal squamous cell carcinoma.OncoTargets and therapy · 2015Article
- Prognostic Impact of ABO Blood Group on the Survival in Patients with Ovarian Cancer.Journal of Cancer · 2015Article
- Histotype-specific copy-number alterations in ovarian cancer.BMC medical genomics · 2012Article
- Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms.Human molecular genetics · 2008Article
- Molecular cytogenetic analysis of gene rearrangements in childhood acute lymphoblastic leukemia.Journal of Korean medical science · 2005Article
- Article
- Article
- Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation.British journal of cancer · 2003Article
- CDKN2A gene inactivation in epithelial sporadic ovarian cancer.British journal of cancer · 1999Article
- Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours.British journal of cancer · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have screened 33 ovarian tumours of various grades and stages for the loss of heterozygosity (LOH) of markers on chromosome 9. LOH was detected in 26 cases (79%). Eleven tumours (33%) showed LOH of all informative markers. The remaining 15 cases had partial deletions. Of these, six (18%) had losses on 9p only, three (9%) had LOH confined to 9q and six (18%) had losses on both chromosome arms, four of which had a retention of hetereozygosity in between. There was no association between tumour grade stage or histopathology and any losses. High-density deletion mapping was carried out in 12 selected cases that had partial deletions of 9p and/or 9q. The deleted region on 9p included the cyclin-dependent kinase inhibitor 2 (CDKN2) locus and one tumour was found to have a homozygous deletion of CDKN2. LOH on 9q extended over a larger region. We found evidence for two regions of deletion on 9q, one at 9q34 and the other encompassing the nevoid basal cell carcinoma (Gorlin) syndrome locus on proximal 9q.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.